361 related articles for article (PubMed ID: 28180966)
1. An update on the role of PET/CT and PET/MRI in ovarian cancer.
Khiewvan B; Torigian DA; Emamzadehfard S; Paydary K; Salavati A; Houshmand S; Werner TJ; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1079-1091. PubMed ID: 28180966
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/CT as a molecular biomarker in ovarian cancer.
Nowosinska E; Avril S; Murray I; Szyszko T; Avril N
Cancer Biomark; 2010-2011; 8(4-5):167-75. PubMed ID: 22045351
[TBL] [Abstract][Full Text] [Related]
4. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer.
Khiewvan B; Torigian DA; Emamzadehfard S; Paydary K; Salavati A; Houshmand S; Shamchi SP; Werner TJ; Aydin A; Roy SG; Alavi A; Kumar R
Hell J Nucl Med; 2016; 19(3):254-268. PubMed ID: 27824966
[TBL] [Abstract][Full Text] [Related]
5. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
7. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
8. PET/CT for Evaluation of Ovarian Cancer.
Kemppainen J; Hynninen J; Virtanen J; Seppänen M
Semin Nucl Med; 2019 Nov; 49(6):484-492. PubMed ID: 31630732
[TBL] [Abstract][Full Text] [Related]
9. Imaging biomarkers in ovarian cancer: the role of ¹⁸F-FDG PET/CT.
Mapelli P; Incerti E; Fallanca F; Gianolli L; Picchio M
Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):93-102. PubMed ID: 26859083
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
12. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
Nasu K; Abe W; Takai N; Tomonari K; Narahara H
Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
14. Present and future of FDG-PET/CT in ovarian cancer.
Kitajima K; Murakami K; Sakamoto S; Kaji Y; Sugimura K
Ann Nucl Med; 2011 Apr; 25(3):155-64. PubMed ID: 21113691
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
16. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
17. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer].
Pöpperl G; Lang S; Dagdelen O; Jäger L; Tiling R; Hahn K; Tatsch K
Rofo; 2002 Jun; 174(6):714-20. PubMed ID: 12063600
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
Nam EJ; Yun MJ; Oh YT; Kim JW; Kim JH; Kim S; Jung YW; Kim SW; Kim YT
Gynecol Oncol; 2010 Mar; 116(3):389-94. PubMed ID: 19926121
[TBL] [Abstract][Full Text] [Related]
20. EANM guideline on the role of 2-[
Delgado Bolton RC; Aide N; Colletti PM; Ferrero A; Paez D; Skanjeti A; Giammarile F
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3286-3302. PubMed ID: 34215923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]